Top Markets
#1 0G 0G +42.31%
#2 Merlin's Seal BTC Merlin's Seal BTC +37.73%
#3 Useless Coin Useless Coin +35.33%
#4 StonkBroker StonkBroker +33.91%
#5 SAFEcoin SAFEcoin +30.67%
#6 Arbitrum Arbitrum +28.52%
#7 Notcoin Notcoin +19.30%
#8 Full Moon Full Moon +18.20%
#9 Zora Zora +17.22%
#10 rsERG rsERG +15.54%
Coin of the day
0G 0G
Settings
Language
ENGLISH
Currency
USD
Theme
Probi AB (publ) Probi AB (publ)

Probi AB (publ)

PROB
Rank in Stocks #14012
Probi AB (publ) specializes in the research, development, manufacturing,... Probi AB (publ) specializes in the research, development, manufacturing, marketing, and distribution of probiotics for the health, pharmaceutical, and food sectors. The company's scientific endeavors primarily focus on areas such as gastrointestinal, digestive, immune, and bone health, as well as iron absorption, and the specific health requirements of children, women, and seniors. Their product range includes dietary supplements and various food and beverage applications, offered in diverse formats like capsules, tablets (including chewable), spheres, powders, and an array of drinks such as fruit drinks, shots, carbonated beverages, and recovery drinks. Probi's products are sold in approximately 40 countries globally. The company also fosters collaborations, including a partnership with Örebro University for exploring needle-free vaccines and with La Trobe University for a clinical trial assessing the effects of Probi Osteo in Australian women. Established in 1991 and headquartered in Lund, Sweden, Probi AB (publ) operates as a subsidiary of Symrise AG.
Share Price
$38.87
Last synced: 2025-02-12
Market Cap
$442.88M
Change (1 day)
21.28%
Change (1 year)
0.00%
Country
SE
Trade Probi AB (publ) (PROB)

Category

Healthcare
P/E ratio for Probi AB (publ) (PROB)
P/E ratio as of 2026 TTM: 0
According to Probi AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Probi AB (publ) from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 38.29 -
IN
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.